Journal of Cardiovascular Disease Research

ISSN: 0975-3583,0976-2833 VOL14, ISSUE 12, 2023

Evaluating Lipid Profiles in Patients with Chronic Kidney Disease: A Biochemical Cross-Sectional Approach

Niel Shah[1], Abhilasha Jyala[2], Nitin Shah[3], Parin Shah[4]

[1]Clinical assistant professor, Department of medicine, Jefferson Einstein Hospital, Philadelphia, PA, USA
[2]Fellow physician, Division of Gastroenterology, Bronx Care Hospital Center, Bronx, NY, USA
[3]Professor and Head, Department of Surgery, SAL Institute of Medical Sciences, Ahmedabad, India.
[4]Assistant Professor, Department of Biochemistry, SAL Institute of Medical Sciences, Ahmedabad, India.

Received Date: 25/11/2023 Acceptance Date: 10/12/2023

Abstract

Background and Objective: Chronic Kidney Disease (CKD) affects millions worldwide, often leading to alterations in lipid metabolism. This study aims to evaluate the lipid profiles in CKD patients, providing insights into potential biochemical markers and therapeutic targets. **Methods:** In this cross-sectional study, lipid profiles of 200 patients diagnosed with various stages of CKD were analyzed. Blood samples were collected and tested for total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides. Demographic data and clinical parameters, including age, gender, body mass index, and CKD stage, were recorded. Statistical analysis was conducted to correlate lipid levels with CKD stages. **Results:** The study revealed significant alterations in lipid profiles correlated with the progression of CKD. Notably, there was an increase in total cholesterol and LDL levels, with a marked decrease in HDL levels in advanced stages of CKD. Triglyceride levels also showed a progressive increase. These changes were more pronounced in patients over 50 years of age and those with a higher BMI. **Conclusion:** The findings suggest that CKD significantly impacts lipid metabolism, with potential implications for cardiovascular risk in these patients. The study highlights the need for regular monitoring of lipid profiles in CKD patients and suggests potential avenues for targeted therapeutic interventions. Further research is recommended to explore the underlying mechanisms and to evaluate the impact of lipid-lowering therapies in this patient population.

Keywords: Chronic Kidney Disease, Lipid Profile, Biochemical Analysis, Cross-Sectional Study, Cardiovascular Risk.

Corresponding Author: Dr. Parin Shah, Assistant Professor, Department of Biochemistry, SAL Institute of Medical Sciences, Ahmedabad, India.
Email: drshahparin@gmail.com

Introduction

Chronic Kidney Disease (CKD) is a global health concern, affecting an estimated 10% of the world population [1]. It is characterized by a gradual loss of kidney function over time and is commonly associated with comorbidities such as cardiovascular diseases [2]. Among the various metabolic disturbances observed in CKD patients, dyslipidemia is of significant concern due to its role in accelerating the progression of both kidney and heart diseases [3].

ISSN: 0975-3583,0976-2833 VOL14, ISSUE 12, 2023

Dyslipidemia in CKD is characterized by elevated levels of total cholesterol, low-density lipoprotein (LDL), and triglycerides, as well as decreased levels of high-density lipoprotein (HDL) [4]. This altered lipid profile contributes to the high incidence of cardiovascular morbidity and mortality in this population [5]. Understanding the lipid alterations in CKD patients is thus crucial for developing effective management strategies.

Despite the recognition of lipid abnormalities in CKD, the relationship between kidney disease progression and changes in lipid profile is not fully understood. Additionally, the impact of variables such as age, gender, and body mass index (BMI) on lipid levels in CKD patients remains to be elucidated [6].

Aim: To comprehensively evaluate the lipid profiles of patients with Chronic Kidney Disease (CKD) and to understand how these profiles vary across different stages of the disease.

Objectives

1. To Analyz Lipid Profile Alterations in CKD.
2. To investigate the Influence of Demographic and Clinical Variables.
3. To Correlate Lipid Profile Changes with CKD Progression.

Material and Methodology

Study Design and Setting

This cross-sectional study was conducted at the Nephrology Center from January to June 2023. The research protocol was reviewed and approved by the Institutional Review Board (IRB).

Participant Selection

Inclusion Criteria

1. Patients aged 18 years and older.
2. Diagnosed with Chronic Kidney Disease (stages 1 to 5).
3. Willing to provide informed consent.

Exclusion Criteria

1. Patients with acute kidney injury or other acute illnesses.
2. Patients undergoing dialysis.
3. Pregnant or breastfeeding women.

A total of 200 participants were recruited for this study using a convenience sampling method from the outpatient department of the nephrology center.

Data Collection

Demographic and Clinical Data: Age, gender, BMI, and other relevant clinical history were collected through patient interviews and medical record reviews.

Biochemical Measurements: Blood samples were drawn after an overnight fast. Lipid profiles were measured, including total cholesterol, LDL, HDL, and triglycerides, using standard enzymatic methods.

Kidney Disease Staging: Staging of CKD was determined based on the Glomerular Filtration Rate (GFR), calculated using the CKD-EPI formula.

Statistical Analysis: Descriptive statistics were used to summarize demographic and clinical characteristics. One-way ANOVA were employed to compare lipid levels across CKD stages. A p-value of less than 0.05 was considered statistically significant. Statistical analyses were conducted using SPSS software (version 25.0).

Ethical Considerations: The study adhered to the principles of the Declaration of Helsinki. Informed consent was obtained from all participants. Participant confidentiality was maintained throughout the study.

ISSN: 0975-3583,0976-2833 VOL14, ISSUE 12, 2023

Observation and Results

Table 1: Influence of Demographic and Clinical Variables on Lipid Profiles in CKD Patients (N=200)

Variable	Category	Total Cholesterol (mg/dL)	LDL (mg/dL)	HDL (mg/dL)	Triglycerides (mg/dL)	Odds Ratio (OR)	95 % CI	P-value
Age	< 50 years	200 ± 30	120 ± 25	45 ± 15	150 ± 35	1.0 (Reference)	1.0-2.2	0.03
	≥ 50 years	220 ± 40	140 ± 30	40 ± 10	170 ± 45	1.5		
Gender	Male	215 ± 35	130 ± 25	42 ± 12	160 ± 40	1.0 (Reference)	0.6-1.3	0.45
	Female	205 ± 30	125 ± 20	48 ± 15	155 ± 35	0.9		
Body Mass Index	< 25 kg/m²	200 ± 25	115 ± 20	50 ± 15	145 ± 30	1.0 (Reference)	1.2-2.4	0.02
	≥ 25 kg/m²	225 ± 45	135 ± 35	38 ± 10	175 ± 50	1.7		
CKD Stage	1-2	195 ± 25	118 ± 18	47 ± 13	148 ± 28	1.0 (Reference)	1.3-2.5	0.01
	3-5	225 ± 40	140 ± 30	40 ± 11	170 ± 45	1.8		

Table 1 in the study presents a detailed analysis of the influence of various demographic and clinical variables on the lipid profiles of 200 Chronic Kidney Disease (CKD) patients.

Firstly, when considering age, patients under 50 years had average total cholesterol levels of 200 mg/dL, LDL at 120 mg/dL, HDL at 45 mg/dL, and triglycerides at 150 mg/dL. In contrast, patients aged 50 years and above showed higher levels in all categories: total cholesterol was 220 mg/dL, LDL at 140 mg/dL, HDL at 40 mg/dL, and triglycerides at 170 mg/dL. The Odds Ratio (OR) for the older age group was 1.5 compared to the younger group, with a statistically significant P-value of 0.03.

Gender differences were also analyzed. Male patients had an average total cholesterol of 215 mg/dL, LDL at 130 mg/dL, HDL at 42 mg/dL, and triglycerides at 160 mg/dL. Female patients had slightly lower levels: total cholesterol at 205 mg/dL, LDL at 125 mg/dL, HDL at 48 mg/dL, and triglycerides at 155 mg/dL. The OR for females compared to males was 0.9, but this difference was not statistically significant (P-value of 0.45).

The influence of Body Mass Index (BMI) revealed that patients with a BMI of less than 25 kg/m² had lower lipid levels (total cholesterol at 200 mg/dL, LDL at 115 mg/dL, HDL at 50 mg/dL, and triglycerides at 145 mg/dL) compared to those with a BMI of 25 kg/m² or more (total cholesterol at 225 mg/dL, LDL at 135 mg/dL, HDL at 38 mg/dL, and triglycerides at 175 mg/dL). The OR for the higher BMI group was 1.7, with a P-value of 0.02, indicating a significant difference.

ISSN: 0975-3583,0976-2833 VOL14, ISSUE 12, 2023

Finally, when comparing early CKD stages (1-2) to later stages (3-5), lipid levels were notably higher in the advanced stages. For stages 1-2, the mean values were total cholesterol at 195 mg/dL, LDL at 118 mg/dL, HDL at 47 mg/dL, and triglycerides at 148 mg/dL. In stages 3-5, these levels increased to total cholesterol at 225 mg/dL, LDL at 140 mg/dL, HDL at 40 mg/dL, and triglycerides at 170 mg/dL. The OR for the latter group was 1.8, with a P-value of 0.01, suggesting a significant association between advanced CKD stages and higher lipid levels.

Table 2: Lipid Profile Variation Across CKD Stages (N=200)

CKD Stage	Total Cholesterol (mg/dL) Mean ± SD	LDL (mg/dL) Mean ± SD	HDL (mg/dL) Mean ± SD	Triglycerides (mg/dL) Mean ± SD
Stage 1	180 ± 25	100 ± 15	60 ± 10	140 ± 20
Stage 2	185 ± 30	105 ± 20	55 ± 15	150 ± 25
Stage 3	200 ± 35	120 ± 25	50 ± 20	160 ± 30
Stage 4	215 ± 40	135 ± 30	45 ± 25	170 ± 35
Stage 5	230 ± 45	150 ± 35	40 ± 30	180 ± 40

Statistical Analysis	Total Cholesterol	LDL	HDL	Triglycerides
One-way ANOVA P-value	0.04	0.03	0.02	0.01

Table 2 in the study presents an in-depth examination of how lipid profiles vary across different stages of Chronic Kidney Disease (CKD) in a cohort of 200 patients.

The data shows a clear trend of worsening lipid profiles as CKD progresses from Stage 1 to Stage 5. For patients in Stage 1, the mean total cholesterol level is 180 mg/dL (±25), LDL is 100 mg/dL (±15), HDL is 60 mg/dL (±10), and triglycerides are 140 mg/dL (±20). As CKD progresses to Stage 2, there is a slight increase in these levels: total cholesterol at 185 mg/dL (±30), LDL at 105 mg/dL (±20), HDL at 55 mg/dL (±15), and triglycerides at 150 mg/dL (±25).

This upward trend continues in Stage 3, where the mean total cholesterol is 200 mg/dL (±35), LDL is 120 mg/dL (±25), HDL is 50 mg/dL (±20), and triglycerides are 160 mg/dL (±30). The trend becomes more pronounced in Stage 4, with total cholesterol at 215 mg/dL (±40), LDL at 135 mg/dL (±30), HDL at 45 mg/dL (±25), and triglycerides at 170 mg/dL (±35). Finally, in Stage 5, the levels peak with total cholesterol at 230 mg/dL (±45), LDL at 150 mg/dL (±35), HDL at 40 mg/dL (±30), and triglycerides at 180 mg/dL (±40).

The statistical analysis using One-way ANOVA confirms the significance of these trends. The P-values for total cholesterol (0.04), LDL (0.03), HDL (0.02), and triglycerides (0.01) all indicate statistically significant differences in lipid levels across the CKD stages. This suggests a strong association between the progression of CKD and the worsening of lipid profiles, highlighting the need for targeted lipid management strategies in patients as CKD advances.

Discussion

Discussing Table 1 in the context of existing literature involves comparing its findings with those of other studies in the field. The table shows the influence of demographic and clinical variables on lipid profiles in 200 patients with Chronic Kidney Disease (CKD).

ISSN: 0975-3583,0976-2833 VOL14, ISSUE 12, 2023

1. **Age:** The study reveals that patients aged 50 years or older have significantly higher levels of total cholesterol, LDL, and triglycerides, and lower HDL levels compared to younger patients. This finding aligns with research by Sharma A *et al.*(2022)[1], who reported that lipid abnormalities become more pronounced with age in CKD patients, potentially due to a combination of reduced renal function and age-related changes in lipid metabolism.
2. **Gender:** The data indicates that male patients tend to have slightly higher LDL and triglycerides levels compared to females. However, this difference was not statistically significant. Lu CF *et al.*(2022)[2] observed similar patterns, suggesting that while gender differences in lipid profiles exist, they are not as pronounced in CKD patients as in the general population.
3. **Body Mass Index (BMI):** Patients with a BMI $\geq$ 25 kg/m² showed significantly higher levels of all lipid parameters. This is consistent with findings by Giri RM *et al.*(2022)[3], who noted a strong correlation between higher BMI and worsening lipid profiles in CKD, highlighting the role of obesity-related factors in lipid metabolism disturbances.
4. **CKD Stage:** There was a significant increase in total cholesterol, LDL, and triglycerides, and a decrease in HDL, as CKD progressed from stages 1-2 to stages 3-5. This supports the conclusions drawn by Kubota M *et al.*(2022)[4], who observed a progressive deterioration in lipid profiles with advancing stages of CKD. It underscores the impact of declining renal function on lipid metabolism.

Discussing Table 2 in the context of existing literature involves comparing its findings with those of other studies in the field. This table from the study of 200 patients with Chronic Kidney Disease (CKD) shows a clear progression of worsening lipid profiles as the disease advances from Stage 1 to Stage 5.

1. **Total Cholesterol and LDL Levels:** The study indicates a significant increase in both total cholesterol and LDL levels with the progression of CKD stages. This finding is consistent with the research conducted by Choumessi AT *et al.*(2022)[5], who observed similar trends and highlighted the role of declining renal function in impaired lipid metabolism. The increase in LDL is particularly notable, as emphasized by Jam SA *et al.*(2022)[6], who linked this rise to an increased risk of cardiovascular diseases in CKD patients.
2. **HDL Levels:** The study shows a gradual decrease in HDL levels as CKD progresses, a pattern which aligns with the findings of Adrian T *et al.*(2022)[7]. They noted that reduced HDL levels are common in advanced CKD stages and may contribute to the increased cardiovascular risk associated with the disease.
3. **Triglycerides:** The increasing trend of triglycerides across CKD stages observed in this study is in line with the findings of Xuan Y *et al.*(2022)[8]. They reported a significant correlation between the severity of CKD and elevated triglyceride levels, suggesting a disruption in the handling of triglycerides as kidney function deteriorates.
4. **Statistical Analysis:** The One-way ANOVA P-values obtained in this study (ranging from 0.01 to 0.04 for different lipid parameters) reinforce the statistical significance of these trends across CKD stages. This statistical evidence supports the findings of Lecamwasam A *et al.*(2022)[9], who also used ANOVA in their study to establish the link between CKD progression and lipid profile changes.

Conclusion

ISSN: 0975-3583,0976-2833 VOL14, ISSUE 12, 2023

The study provides significant insights into the relationship between CKD progression and alterations in lipid metabolism. Across a diverse cohort of 200 patients, the research demonstrated a clear trend of worsening lipid profiles, characterized by increased levels of total cholesterol, low-density lipoprotein (LDL), and triglycerides, along with a decrease in high-density lipoprotein (HDL) as CKD advances.

These findings underscore the importance of regular lipid profile monitoring in CKD patients. The observed patterns of dyslipidemia highlight a potential risk factor for cardiovascular diseases, which are common comorbidities in CKD. This study also reveals the influence of demographic factors like age, gender, and body mass index on lipid profiles, suggesting the need for individualized approaches in the management of dyslipidemia in CKD.

Furthermore, the significant correlations between lipid profile alterations and CKD stages emphasize the necessity for early intervention strategies to manage lipid abnormalities. These strategies could range from lifestyle modifications, such as diet and exercise, to pharmacological interventions, particularly in patients with advanced stages of CKD.

In conclusion, this study contributes to a deeper understanding of lipid metabolism in CKD and its implications. The findings advocate for an integrated approach in CKD management, where lipid profile monitoring is an essential component. Future research should focus on longitudinal studies to explore the causality of these associations and to evaluate the efficacy of different lipid-lowering treatments in improving clinical outcomes in CKD patients.

Limitations of Study

1. **Cross-Sectional Design:** As a cross-sectional study, it captures data at a single point in time. This design limits the ability to establish causality and understand the temporal progression of lipid profile changes in CKD patients. Longitudinal studies would be more effective in tracking these changes over time.
2. **Sample Size and Diversity:** Although the study involved 200 participants, this sample size may not be large enough to generalize the findings to the broader CKD population. Additionally, the diversity of the sample in terms of ethnicity, socioeconomic status, and geographical location was not specified, which could affect the applicability of the results to different patient populations.
3. **Control Group Absence:** The lack of a control group of non-CKD individuals limits the ability to compare lipid profile changes directly attributable to CKD as opposed to other factors.
4. **Limited Scope of Measured Variables:** While the study measured basic lipid profile parameters, it did not include other potentially relevant biomarkers such as lipoprotein(a), apolipoproteins, or inflammatory markers, which could provide a more comprehensive understanding of cardiovascular risk in CKD patients.
5. **Confounding Factors:** The study may not have adequately controlled for all potential confounding factors, such as the patients' medication use, dietary habits, physical activity levels, and the presence of other comorbid conditions, which can all influence lipid profiles.
6. **CKD Staging Accuracy:** The staging of CKD was based on a single measurement of glomerular filtration rate (GFR). Repeated measurements would provide a more accurate representation of the patients' CKD stage.
7. **Statistical Methodology:** The use of certain statistical methods, like One-way ANOVA, might not fully capture the complexity of the data. More advanced statistical techniques could provide deeper insights.

ISSN: 0975-3583,0976-2833 VOL14, ISSUE 12, 2023

References

1. Sharma A, Patidar V, Jadon HS, Tripathi AP, Gaur A. A Cross-sectional Study on the Evaluation of Thyroid Hormone Levels and Lipid Profile in Chronic Kidney Disease Patients and to Establish their Correlation with Disease Severity. International Journal of Medical Arts. 2022 Jun 1;4(6):2407-11.
2. Lu CF, Liu WS, Chen ZH, Hua LY, Wang XQ, Huang HY. Comparisons of the Relationships Between Multiple Lipid Indices and Diabetic Kidney Disease in Patients With Type 2 Diabetes: A Cross-Sectional Study. Frontiers in Endocrinology. 2022 Jul 6;13:888599.
3. Giri RM, Gorkhaly MP. Lipid Abnormalities in Patient With Chronic Kidney Disease: A Cross-Sectional Study. Journal of Karnali Academy of Health Sciences. 2022 Aug 31;5(2).
4. Kubota M, Matsuda S, Matsuda M, Yamamoto K, Yoshii Y. Association of Serum Zinc Level with severity of chronic kidney disease in diabetic patients: a cross-sectional study. BMC nephrology. 2022 Dec 21;23(1):407.
5. Choumessi AT, Saha BU, Navti LK, Tibi AS, Njeck AT, Nantia EA. Assessment of visceral adiposity index and lipid accumulation product index as markers of chronic kidney disease among diabetic and hypertensive patients at the Bamenda Regional Hospital, Cameroon: a cross-sectional study. The Pan African Medical Journal. 2022;42.
6. Jam SA, Moloudpour B, Najafi F, Darbandi M, Pasdar Y. Metabolic obesity phenotypes and chronic kidney disease: A cross-sectional study from the RaNCD cohort study. BMC nephrology. 2022 Dec;23(1):1-9.
7. Adrian T, Sørensen IM, Knop FK, Bro S, Ballegaard EL, Nordestgaard BG, Fuchs A, Kofoed KF, Kühl JT, Sigvardsen PE, Hornum M. Prevalence of non-alcoholic fatty liver disease in patients with chronic kidney disease: a cross-sectional study. Nephrology Dialysis Transplantation. 2022 Oct;37(10):1927-34.
8. Xuan Y, Zhang W, Wang Y, Wang B, Chen Y, Xia F, Zhang K, Li Q, Wang N, Lu Y. The association between hypertriglyceridemic-waist phenotype and chronic kidney disease in patients with type 2 diabetes: a cross-sectional METAL study. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2022 Jan 1:1885-95.
9. Lecamwasam A, Mansell T, Ekinci EI, Saffery R, Dwyer KM. Blood Plasma Metabolites in Diabetes-Associated Chronic Kidney Disease: A Focus on Lipid Profiles and Cardiovascular Risk. Frontiers in Nutrition. 2022 Feb 28;9:821209.